The researchers note that these problems probably didn’t show up in the clinical trials that led to the dugs approval because those studies weren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving their underlying causes|The researchers note that tese problems probably didn’t show up in the clinical trials that led to the dugs approval because those studies weren’t large enough to capture some of tese rarer adverse events or the studies recorded tese events as symptoms rather than delving their underlying causes
The researchers note that these problems probably didn’t show up in the clinical trials that led to the dugs approval because those studies weren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving their underlying causes|The researchers note that these problems probably didn’t show up in the clinical trials that led to the dugs approval because those studies weren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving thei underlying causes
The researchers note that these problems probably didn’t show up in the clinical trials that led to the dugs approval because those studies weren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving their underlying causes|The researchers note that these problems probably didn’t show up in the clinical trials that led to the dugs approval because those studies weren’t large enough to capture some of these rarer adverse event or the studies recorded these event as symptoms rather than delving their underlying causes
The researchers note that these problems probably didn’t show up in the clinical trials that led to the dugs approval because those studies weren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving their underlying causes|The researchers tone that these problems probably didn’t show up in the clinical trials that led to the dugs approval because those studies weren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving their underlying causes
The researchers note that these problems probably didn’t show up in the clinical trials that led to the dugs approval because those studies weren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving their underlying causes|The researchers note thfat these problems probably didn’t show up in the clinical trials thfat led to the dugs approval because those studies weren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving their underlying causes
The researchers note that these problems probably didn’t show up in the clinical trials that led to the dugs approval because those studies weren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving their underlying causes|The researchers note that these problems probably didn’t show up in the clinical trials that led to the dugs approval becauske those studies weren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving their underlying causes
The researchers note that these problems probably didn’t show up in the clinical trials that led to the dugs approval because those studies weren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving their underlying causes|The researchers note that these problems probably didn’t show up in the clinical trials that led to the dugs approval because those studies ewren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving their underlying causes
The researchers note that these problems probably didn’t show up in the clinical trials that led to the dugs approval because those studies weren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving their underlying causes|The researchers note that these problems probably didn’t show up in the cliical trials that led to the dugs approval because those studies weren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving their underlying causes
The researchers note that these problems probably didn’t show up in the clinical trials that led to the dugs approval because those studies weren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving their underlying causes|The researchers note that these problems probably didn’t show up in the clinical trials that led to the dugs approval because those studies weren’t large enough to capture some of these rare adverse events or the studies recorded these events as symptoms rather than delving their underlying causes
The researchers note that these problems probably didn’t show up in the clinical trials that led to the dugs approval because those studies weren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving their underlying causes|The researchers note that these problems probably didn’t show up in the clinical trials that ed to the dugs approval because those studies weren’t large enough to capture some of these rarer adverse events or the studies recorded these events as symptoms rather than delving their underlying causes
